Cite
MLA Citation
Andreas Schneeweiss et al.. “Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.” European journal of cancer, vol. 160, 2022, pp. 100–111. http://access.bl.uk/ark:/81055/vdc_100148048750.0x000048